Literature DB >> 11380821

Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure.

N D Vaziri1, K Liang, J S Parks.   

Abstract

BACKGROUND: Chronic renal failure (CRF) is associated with premature arteriosclerosis, impaired high-density lipoprotein (HDL) maturation, increased pre-beta HDL (a lipid-poor HDL species), reduced HDL/total cholesterol ratio, hypertriglyceridemia, and depressed lipolytic activity. The latter has been, in part, attributed to elevated pre-beta HDL, which is a potent inhibitor of lipoprotein lipase (LPL). Accumulation of cholesterol in the arterial wall is a critical step in atherogenesis, and HDL-mediated cholesterol removal from peripheral tissues mitigates atherosclerosis. Lecithin:cholesterol acyltransferase (LCAT) is essential for maturation of HDL and cholesterol removal by HDL from peripheral tissues. Earlier studies have revealed depressed plasma LCAT enzymatic activity in patients with CRF. This study was conducted to determine whether impaired LCAT activity can be confirmed in CRF animals and if so whether it is due to down-regulation of hepatic LCAT expression.
METHODS: Hepatic tissue LCAT mRNA and plasma LCAT enzymatic activity were measured in male Sprague-Dawley rats six weeks after excisional 5/6 nephrectomy or sham operation.
RESULTS: Compared with the controls, the CRF group exhibited a significant reduction of hepatic tissue LCAT mRNA abundance. The reduction in hepatic LCAT mRNA was accompanied by a marked reduction of plasma LCAT activity and elevation of serum-free cholesterol in the CRF animals. LCAT activity correlated positively with the HDL/total cholesterol ratio and inversely with free cholesterol and triglyceride concentrations.
CONCLUSIONS: CRF leads to a marked down-regulation of hepatic LCAT mRNA expression and plasma LCAT activity. This abnormality can impair HDL-mediated cholesterol uptake from the vascular tissue and contribute to cardiovascular disease. In addition, LCAT deficiency can, in part, account for elevated serum-free cholesterol, reduced HDL/total cholesterol, and elevated pre-beta HDL in CRF. The latter can, in turn, depress lipolytic activity and hinder triglyceride-rich lipoprotein clearance in CRF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380821     DOI: 10.1046/j.1523-1755.2001.00734.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  46 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.

Authors:  Nosratola D Vaziri; Kaveh Navab; Pavan Gollapudi; Hamid Moradi; Madeleine V Pahl; Cyril H Barton; Alan M Fogelman; Mohamad Navab
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

Review 3.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

Review 4.  Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Clin Exp Nephrol       Date:  2013-08-24       Impact factor: 2.801

Review 5.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

Review 6.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

7.  Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study.

Authors:  Ching-Wei Tsai; Han-Chun Huang; Hsiu-Yin Chiang; Chih-Wei Chung; Shih-Ni Chang; Pei-Lun Chu; Chin-Chi Kuo
Journal:  J Lipid Res       Date:  2019-01-14       Impact factor: 5.922

8.  Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).

Authors:  Madeleine V Pahl; Zhenmin Ni; Lili Sepassi; Hamid Moradi; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2009-03-18       Impact factor: 5.992

Review 9.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

10.  High-calorie diet partially ameliorates dysregulation of intrarenal lipid metabolism in remnant kidney.

Authors:  Hyun Ju Kim; Jun Yuan; Keith Norris; Nosratola D Vaziri
Journal:  J Nutr Biochem       Date:  2009-12-01       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.